Another Phase II, crossover study of ataluren (NCT02758626) is ongoing for the treatment of drug-resistent epilepsy caused by Dravet syndrome and cyclin-dependent kinase-like 5 (CDKL5) deficiency. The gene discussed is CDKL5; the disease is encephalopathy, progressive, early-onset, with brain edema and/or leukoencephalopathy.